Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.71 |
| ▸ | CES1 | P23141 | 3/20 | 0.71 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | OGG1 | O15527 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557285 | 0.84 | CES2 (1.00) | CES2CES1CA1CA2HTT | |
| SCHEMBL10888312 | 0.81 | CES2 (0.65) | CES2CES1CA1CA2HTT | |
| SCHEMBL28385234 | 0.79 | CES2 (0.62) | CES2CES1CA1CA2HTT | |
| SCHEMBL13444902 | 0.79 | CES2 (0.64) | CES2CES1KMT2AL3MBTL1LMNA | |
| SCHEMBL17187852 | 0.79 | CES2 (0.62) | CES2CES1CA1CA2GSK3B | |
| SCHEMBL20102 | 0.79 | CES2 (0.62) | CES2CES1CA1CA2GSK3B | |
| SCHEMBL5388314 | 0.78 | CES2 (0.76) | CES2CES1CA1CA2HTT | |
| SCHEMBL11372320 | 0.78 | CES2 (0.60) | CES2CES1CA1CA2HTT | |
| SCHEMBL10813399 | 0.78 | CES2 (0.60) | CES2CES1CA1CA2HTT | |
| SCHEMBL10813395 | 0.78 | CES2 (0.60) | CES2CES1CA1CA2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094688-A | Compositions and methods for treating pulmonary arterial hypertension | — | 2026-05-26 | — | — | CN | disclosed |
| US-20250381196-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-20250241908-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES | NINGBO MEISHAN BONDED PORT AREA ZHEJIANG UNITED INVESTMENT MANAGEMENT CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| CN-119997953-A | Alpha protein kinase 1 inhibitors for the treatment of kidney diseases and kidney related diseases | 上海药苑生物科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4543443-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | Shanghai Yao Yuan Biotechnology Co., Ltd. (CN) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025082485-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-24 | — | — | WO | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| CN-118103045-A | Alpha protein kinase 1 inhibitors for the treatment of kawasaki disease | 上海药苑生物科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20170368032-A1 | Imidazole-Based Antimicrobial Agents | PROCOMCURE BIOTECH GMBH (AT) | 2017-12-28 | — | — | US | disclosed |
| US-20170340613-A1 | Novel Imidazole-Based Heterocyclic Compounds | PROCOMCURE BIOTECH GMBH (AT) | 2017-11-30 | — | — | US | disclosed |
| US-20170334887-A1 | Imidazole-Based Antimicrobial Agents | PROCOMCURE BIOTECH GMBH (AT) | 2017-11-23 | — | — | US | disclosed |
| EP-3226858-A1 | IMIDAZOLE-BASED ANTIMICROBIAL AGENTS | Procomcure Biotech GmbH (AT) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016087616-A1 | IMIDAZOLE-BASED ANTIMICROBIAL AGENTS | PROCOMCURE BIOTECH GMBH (AT) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087618-A1 | IMIDAZOLE-BASED ANTIMICROBIAL AGENTS | PROCOMCURE BIOTECH GMBH (AT) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087615-A1 | NOVEL IMIDAZOLE-BASED HETEROCYCLIC COMPOUNDS | PROCOMCURE BIOTECH GMBH (AT) | 2016-06-09 | — | — | WO | disclosed |
| EP-2619200-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012040511-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | PHKA1, PHKA2, PHKG1 | CES2 3819/4885CES1 943/4885CA1 3695/4885 |
| US-20170334887-A1 | Imidazole-Based Antimicrobial Agents | TLR5, NISCH, SLC11A2 | CES2 3407/4885CES1 2890/4885CA1 4811/4885 |
| US-20250241908-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES | PHKA1, PHKA2, PHKG1 | CES2 3744/4885CES1 369/4885CA1 4741/4885 |
| US-20170368032-A1 | Imidazole-Based Antimicrobial Agents | TLR5, NISCH, SLC11A2 | CES2 3407/4885CES1 2890/4885CA1 4811/4885 |
| US-20250381196-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | PHKA1, PHKA2, PHKG1 | CES2 4417/4885CES1 715/4885CA1 4554/4885 |
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | CES2 2132/4885CES1 2069/4885CA1 1250/4885 |
| US-20170340613-A1 | Novel Imidazole-Based Heterocyclic Compounds | SLC11A2, MIF, NISCH | CES2 2382/4885CES1 1767/4885CA1 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.